ArticleContraception and reproductive medicine2025
Long-acting reversible contraception initiation after medication abortion: a retrospective cohort study.
Article in Contraception and reproductive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedication abortion (MAB) accounts for an increasing proportion of in-clinic abortions in the United States and poses unique considerations for provision of long-acting reversible contraception (LARC). Studies of LARC initiation among MAB patients mostly consist of trials where financial barriers to LARC were removed. We sought to identify correlates of LARC initiation post-MAB in a community-based setting.
methodsThis is a retrospective cohort study of patients who presented to a Planned Parenthood Health Center in Minnesota in 2016 for MAB, chose LARC as their intended post-abortion contraceptive method in counseling, and returned to the clinic for their routine follow-up visit (n = 335). We abstracted sociodemographic and reproductive health history variables and used logistic regression to estimate odds ratios (ORs) for LARC initiation post-abortion (≤ 30 days of mifepristone administration).
resultsStudy participants predominantly self-identified as non-Hispanic and White and had a mean age of 26 years. Overall, 72.8% (n = 244) initiated their desired LARC method by 30 days post-abortion. There was no significant (p < 0.05) association between LARC initiation and most variables: race, ethnicity, age, distance from clinic, body mass index, gestational age, gravidity, prior abortions, and number of children. However, odds of LARC initiation were significantly lower among participants who did not use any health insurance (vs. private insurance) for contraceptive coverage at their MAB follow-up visit (age-adjusted OR 0.35, 95% CI 0.18-0.69). Findings were similar for initiation of the IUD, specifically (age-adjusted OR 0.42, 95% CI 0.18-0.97), but not statistically significant for the implant.
conclusionsLack of health insurance may be a barrier to LARC initiation for MAB patients. Facilitators of LARC initiation in the context of MAB remain unclear and warrant further research to optimize patient-centered care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.